Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEVIMELINE HYDROCHLORIDE vs MYOTONACHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cevimeline is a muscarinic cholinergic agonist that binds to M1 and M3 receptors, stimulating salivary gland secretion.
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
Treatment of dry mouth in patients with Sjögren's syndrome
FDA-approved: Treatment of acute postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the bladder.,Off-label: Treatment of gastroesophageal reflux disease; management of chronic intestinal pseudo-obstruction; treatment of xerostomia (dry mouth) in Sjögren's syndrome or radiation-induced.
30 mg orally three times daily. May increase to 60 mg three times daily if needed.
25 mg orally three times daily. Maximum dose 100 mg four times daily.
The terminal elimination half-life is approximately 3–4 hours in patients with normal renal function, supporting three-times-daily dosing.
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Primarily metabolized by CYP2D6 and CYP3A3/4; also undergoes CYP2C19 and CYP3A5 metabolism.
Bethanechol is primarily metabolized via hydrolysis by plasma esterases (pseudocholinesterases) to inactive metabolites. Minimal hepatic metabolism occurs.
Cevimeline is primarily eliminated via renal excretion (approximately 80% of the dose as unchanged drug and metabolites) and biliary/fecal excretion (approximately 20%).
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Approximately 20% bound to plasma proteins (mainly albumin).
~30%, bound primarily to albumin.
Volume of distribution is approximately 1.2 L/kg, indicating extensive extravascular distribution into tissues.
0.3-0.6 L/kg, indicating distribution into total body water.
Absolute oral bioavailability is approximately 30–40% due to first-pass metabolism.
Oral: 10-20% (extensive first-pass metabolism); Subcutaneous: ~80%; Intravenous: 100%.
No specific adjustment required; use caution in severe renal impairment (Cr Cl <30 m L/min).
GFR 30-59 m L/min: 25 mg twice daily. GFR 15-29 m L/min: 25 mg once daily. GFR <15 m L/min: not recommended.
Child-Pugh Class A and B: No adjustment. Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: 25 mg twice daily. Child-Pugh C: not recommended.
Not FDA approved for pediatric use; safety and efficacy not established.
0.5-1 mg/kg orally three times daily; maximum 25 mg per dose.
No specific dose adjustment, but consider age-related renal decline and potential for increased anticholinergic effects.
Start at 25 mg twice daily due to increased anticholinergic sensitivity.
None
None
Use with caution in patients with cardiovascular disease, asthma, chronic bronchitis, COPD, cholelithiasis, nephrolithiasis, or biliary tract disorders; may cause visual disturbances including decreased visual acuity, especially at night; contraindicated in patients with uncontrolled asthma, narrow-angle glaucoma, or acute iritis.
May cause reflex tachycardia due to hypotension; caution in patients with coronary artery disease, bradycardia, or recent myocardial infarction. Increased vagal tone may precipitate asthma attacks; avoid in asthmatics. May cause exacerbation of peptic ulcer disease. Can increase ureteral pressure; avoid in ureteral obstruction. Use cautiously in patients with epilepsy or hyperthyroidism. Monitor for cholinergic crisis (salivation, lacrimation, urination, defecation, emesis).
Uncontrolled asthma,Narrow-angle glaucoma,Acute iritis
Absolute: Hypersensitivity to bethanechol; mechanical obstruction of the gastrointestinal or urinary tract; recent gastrointestinal anastomosis or bladder surgery; hyperthyroidism; peptic ulcer disease; asthma; epilepsy; Parkinsonism; hypotension; bradycardia; coronary artery disease. Relative: Pregnancy (C); nursing mothers; patients with vagotonia or receiving quinidine or procainamide.
No significant food interactions; however, high-fat meals may delay absorption. Avoid excessive caffeine as it may exacerbate side effects like tachycardia.
Food decreases absorption; take on an empty stomach. Avoid high-fat meals as they may increase side effects. No known specific food interactions.
Pregnancy Category C. In animal studies, cevimeline caused reduced fetal weight and increased skeletal variations at doses 0.1 times the maximum recommended human dose. No adequate human studies. Risk cannot be ruled out; use only if benefit justifies potential risk. First trimester: unknown risk. Second/third trimesters: unknown risk.
Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies. Second trimester: Potential for premature labor due to cholinergic stimulation. Third trimester: Increased risk of uterine hyperstimulation and fetal distress if used for labor induction. Avoid use during pregnancy unless clearly needed.
No data on excretion in human milk. M/P ratio unknown. Caution should be exercised; consider developmental benefits of breastfeeding vs. mother's need for drug.
Excreted in human milk in low concentrations. M/P ratio not established. Caution advised. Potential for cholinergic adverse effects in the infant (e.g., diarrhea, increased secretions). Use only if benefit outweighs risk.
No established dosing guidelines for pregnancy. Pharmacokinetic changes in pregnancy may alter drug exposure, but no specific dose adjustments recommended due to lack of data. Use lowest effective dose if necessary.
No standard dose adjustments recommended due to limited pharmacokinetic data in pregnancy. However, increased plasma volume and renal clearance may necessitate dose titration based on clinical response. Use lowest effective dose and monitor for maternal cholinergic toxicity.
Cevimeline is a muscarinic agonist with higher affinity for M3 receptors, making it effective for xerostomia in Sjögren's syndrome. Avoid in patients with uncontrolled asthma, narrow-angle glaucoma, or iritis. Monitor for excessive sweating and bradycardia. Can be combined with pilocarpine but increase vagal tone risk.
MYOTONACHOL (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for bradycardia and bronchospasm, especially in patients with asthma or cardiac disease. Administer on an empty stomach to reduce nausea. Avoid use in patients with GI obstruction or recent bladder surgery. Atropine should be readily available as an antidote.
Take with or without food, but taking after meals may reduce nausea.,Avoid driving or operating machinery if you experience blurred vision or dizziness.,Drink plenty of water to prevent dehydration from sweating.,Report symptoms like slow heart rate, chest pain, or difficulty breathing immediately.,Do not stop abruptly; consult your doctor for dose adjustments.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Avoid alcohol and caffeine, as they may worsen side effects.,Report symptoms like slow heart rate, wheezing, dizziness, or excessive sweating.,Do not drive or operate heavy machinery until you know how this drug affects you.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.
"Cevimeline, a muscarinic cholinergic agonist, can decrease the metabolism of Betaxolol, a selective beta1-adrenergic receptor antagonist, by competitively inhibiting CYP2D6, a key enzyme responsible for Betaxolol's hepatic clearance. This pharmacokinetic interaction may lead to elevated plasma concentrations of Betaxolol, increasing its beta-blocking effects and potentially causing excessive bradycardia, hypotension, and bronchospasm, particularly in patients with pre-existing cardiac or respiratory conditions."
"Cevimeline, a muscarinic agonist used for xerostomia, can inhibit the metabolism of diphenhydramine by competitively blocking cytochrome P450 (CYP) 2D6 and 3A4 enzymes. This results in reduced clearance of diphenhydramine, leading to elevated plasma concentrations and increased risk of anticholinergic side effects such as sedation, confusion, dry mouth, blurred vision, and urinary retention. Clinically, patients may experience enhanced and prolonged central nervous system depression and anticholinergic toxicity."
"Bopindolol, a non-selective beta-adrenergic antagonist, may inhibit the bronchodilatory effects of cevimeline, a muscarinic agonist that stimulates salivary secretion partly via beta-adrenergic pathways. This can exacerbate cevimeline's parasympathomimetic adverse effects such as bradycardia, hypotension, and bronchoconstriction, particularly in patients with cardiovascular or respiratory comorbidities. Clinically, the combination may lead to increased incidence of symptomatic bradycardia and reduced therapeutic efficacy of cevimeline in managing xerostomia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEVIMELINE HYDROCHLORIDE vs MYOTONACHOL, answered by our medical review team.
CEVIMELINE HYDROCHLORIDE is a Cholinergic agonist (sialogogue) that works by Cevimeline is a muscarinic cholinergic agonist that binds to M1 and M3 receptors, stimulating salivary gland secretion.. MYOTONACHOL is a Cholinergic Agonist that works by Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEVIMELINE HYDROCHLORIDE and MYOTONACHOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEVIMELINE HYDROCHLORIDE is: 30 mg orally three times daily. May increase to 60 mg three times daily if needed.. The standard adult dose of MYOTONACHOL is: 25 mg orally three times daily. Maximum dose 100 mg four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEVIMELINE HYDROCHLORIDE and MYOTONACHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEVIMELINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. In animal studies, cevimeline caused reduced fetal weight and increased skeletal variations at doses 0.1 times the maximum recommended human dose. No adequate. MYOTONACHOL is classified as Category C. Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.